Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
0.877
+0.004 (0.47%)
Jan 30, 2025, 4:00 PM EST - Market closed
Rallybio Employees
Rallybio had 43 employees as of December 31, 2023. The number of employees increased by 2 or 4.88% compared to the previous year.
Employees
43
Change (1Y)
2
Growth (1Y)
4.88%
Revenue / Employee
$13,907
Profits / Employee
-$1,557,512
Market Cap
36.36M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 43 | 2 | 4.88% |
| Dec 31, 2022 | 41 | 6 | 17.14% |
| Dec 31, 2021 | 35 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
RLYB News
- 20 days ago - Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 - Business Wire
- 7 weeks ago - Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting - Business Wire
- 2 months ago - Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 - Business Wire
- 2 months ago - Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women - Business Wire
- 2 months ago - Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference - Business Wire
- 2 months ago - Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor - Business Wire
- 2 months ago - Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 - Business Wire
- 3 months ago - Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - Business Wire